Antiplatelet and antithrombin strategies in acute coronary syndrome: state-of-the-art review

Area of Science:

• Cardiology
• Pharmacology
• Internal Medicine

Background:

• Antiplatelet and antithrombotic agents are crucial in managing acute coronary syndromes (ACS).
• Therapeutic options have expanded significantly over the last two decades.
• Early guidelines recommended limited agents, unlike current comprehensive approaches.

Purpose of the Study:

• To review the mechanism, efficacy, and safety of novel antiplatelet and antithrombotic agents for ACS.
• To examine clinical trial evidence for these advanced therapies.
• To highlight progress in balancing treatment efficacy with reduced bleeding complications.

Main Methods:

• Review of P2Y12 receptor antagonists, glycoprotein IIb/IIIa inhibitors, PAR-1 inhibitors, bivalirudin, fondaparinaux, and rivaroxaban.
• Analysis of clinical trial data on efficacy and safety profiles.
• Synthesis of current evidence on pharmacological management of ACS.

Main Results:

• Numerous newer agents offer improved efficacy and safety compared to older therapies.
• Research focuses on optimizing treatment to enhance effectiveness and minimize bleeding.
• Specific drug classes reviewed include P2Y12 inhibitors, GPIs, PAR-1 inhibitors, and anticoagulants.

Conclusions:

• Contemporary ACS management relies on a broad spectrum of advanced antiplatelet and antithrombotic agents.
• Ongoing research aims to further refine therapeutic strategies for ACS patients.
• The evolution of these agents reflects significant pharmacological and clinical advancements.